Detalles de la búsqueda
1.
Evolution of COVID-19 symptoms during the first 9 months after illness onset
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21256710
2.
SARS-CoV-2 infection activates dendritic cells via cytosolic receptors rather than extracellular TLRs
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-458667
3.
An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-222232
4.
Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20249035
5.
Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-516125
6.
Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-521247
7.
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-430500
8.
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-430866
9.
The impact of Spike mutations on SARS-CoV-2 neutralization
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-426849
10.
SARS-CoV-2 Infection and Transmission Depends on Heparan Sulfates and Is Blocked by Low Molecular Weight Heparins
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-255810
11.
Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-233536
12.
Breastmilk; a source of SARS-CoV-2 specific IgA antibodies
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20176743
13.
Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20120345
14.
Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-CoV-2 variants
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21264163
15.
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21256092
16.
Single-dose SARS-CoV-2 vaccine in a prospective cohort of COVID-19 patients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21257797
17.
Broad SARS-CoV-2 Neutralization by Monoclonal and Bispecific Antibodies Derived from a Gamma-infected Individual
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-512216
18.
Afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-099507
19.
SARS-CoV-2 recruits a haem metabolite to evade antibody immunity
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21249203
20.
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21257441